文献速递血管炎

特发性结节性多动脉炎、肉芽肿性多血管炎和显微镜下多血管炎患者中ADA2有害基因变异的序列筛查

Sequence-Based Screening of Patients With Idiopathic Polyarteritis Nodosa, Granulomatosis With Polyangiitis, and Microscopic Polyangiitis for Deleterious Genetic Variants in ADA2.
PubMed 文献 · Arthritis Rheumatol · 2021-02-03

本研究对118例特发性结节性多动脉炎(PAN)和1107例肉芽肿性多血管炎(GPA)或显微镜下多血管炎(MPA)患者进行ADA2基因测序,发现7.6%的PAN患者携带罕见非 synonymous 变异,其中3.4%为双等位基因致病/可能致病变异,且这些患者诊断年龄更轻;GPA/MPA患者中未发现双等位基因变异。鉴于TNF抑制剂对DADA2有效而非PAN常规治疗,建议对HBV阴性特发性PAN患者考虑ADA-2检测。

要点

  • 7.6%的特发性PAN患者携带ADA2罕见非 synonymous 变异,3.4%为双等位基因致病/可能致病变异。
  • 携带双等位基因变异的PAN患者诊断年龄更轻,但无其他临床差异。
  • GPA/MPA患者中未发现ADA2双等位基因变异。

核心结论

  • 部分特发性PAN患者符合DADA2的遗传学标准,建议对HBV阴性特发性PAN患者考虑ADA-2检测。

研究设计与样本

  • 对118例特发性PAN患者和1107例GPA或MPA患者进行ADA2基因测序筛查罕见非 synonymous 变异,并对部分血清样本评估ADA-2酶活性。

主要发现

  • 118例PAN患者中9例(7.6%)携带ADA2罕见非 synonymous 变异,其中4例(3.4%)为双等位基因致病/可能致病变异,5例(4.2%)为单等位基因携带者(3个意义不明变异和2个可能致病变异)。
  • 2例携带双等位基因变异的PAN患者血清ADA-2酶活性显著降低。
  • 额外86例患者的ADA-2酶检测发现1例酶活性强烈降低但未检测到致病变异。
  • 携带ADA2双等位基因变异的PAN患者诊断年龄较携带1个或无变异者更年轻,无其他临床差异。
  • GPA或MPA患者中无人携带ADA2双等位基因变异。

关键数值与推荐

  • PAN患者中ADA2罕见非 synonymous 变异频率为7.6%(9/118),双等位基因致病/可能致病变异频率为3.4%(4/118)。
  • GPA/MPA患者(n=1107)中未发现ADA2双等位基因变异。

临床怎么用

  • 对HBV阴性特发性PAN患者应强烈考虑进行ADA-2检测,以识别可能受益于TNF抑制剂治疗的DADA2患者。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Deficiency of adenosine deaminase 2 (DADA2) is a monogenic form of vasculitis that can resemble polyarteritis nodosa (PAN). This study was undertaken to identify potential disease-causing sequence variants in ADA2 in patients with idiopathic PAN, granulomatosis with polyangiitis (GPA), or microscopic polyangiitis (MPA). METHODS: Patients with idiopathic PAN (n = 118) and patients with GPA or MPA (n = 1,107) were screened for rare nonsynonymous variants in ADA2 using DNA sequencing methods. ADA-2 enzyme activity was assessed in selected serum samples. RESULTS: Nine of 118 patients with PAN (7.6%) were identified as having rare nonsynonymous variants in ADA2. Four patients (3.4%) were biallelic for pathogenic or likely pathogenic variants, and 5 patients (4.2%) were monoallelic carriers for 3 variants of uncertain significance and 2 likely pathogenic variants. Serum samples from 2 patients with PAN with biallelic variants were available and showed markedly reduced ADA-2 enzyme activity. ADA-2 enzyme testing of 86 additional patients revealed 1 individual with strongly reduced ADA-2 activity without detectable pathogenic variants. Patients with PAN and biallelic variants in ADA2 were younger at diagnosis than patients with 1 or no variant in ADA2, with no other clinical differences noted. None of the patients with GPA or MPA carried biallelic variants in ADA2. CONCLUSION: A subset of patients with idiopathic PAN meet genetic criteria for DADA2. Given that tumor necrosis factor inhibition is efficacious in DADA2 but is not conventional therapy for PAN, these findings suggest that ADA-2 testing should strongly be considered in patients with hepatitis B virus-negative idiopathic PAN.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Schnappauf O, Sampaio Moura N, Aksentijevich I, et al. Sequence-Based Screening of Patients With Idiopathic Polyarteritis Nodosa, Granulomatosis With Polyangiitis, and Microscopic Polyangiitis for Deleterious Genetic Variants in ADA2. Arthritis Rheumatol. 2021. PMID: 33021335. doi:10.1002/art.41549

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。